Maxim Upgrades Onconova To Buy, Establishes $3 Price Target As Maxim Says The Co. Cleared A Major FInancing Roadblock, Believes Rigosertib Could Emerge As First Targeted Therapy Approved For MDS Based On Mechanism Of Action And Both Prior, Emerging Data